Recent developments in targeting liver fibrosis

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 1, 2008, Pages 29-31

  Iredale, John ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYTOKINE; MATRIX PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CELL LINEAGE; CELL PROLIFERATION; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; MACROPHAGE; MYOFIBROBLAST; REVIEW; STELLATE CELL; STEM CELL;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER CIRRHOSIS; STEM CELL TRANSPLANTATION; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 39149125148     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006;43:S82-8.
2. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004;1:98-105.
3. Russo FP, Alison MR, Bigger BW et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006;130:1807-21.
4. Forbes SJ, Russo FP, Rey V et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004;126:955-63.
5. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001;34:859-67.
6. Zhou X, Hovell CJ, Pawley S et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int 2004;24:492-501.
7. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373-84.
8. Duffield JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005;115:56-65.
9. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996;110:821-31.
10. Iredale JP, Benyon RC, Arthur MJ et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996;24:176-84.
11. Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Heptatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-49.
12. Issa R, Zhou X, Constandinou CM et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795-808.
13. Parsons CJ, Bradford BU, Pan CQ et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody in established liver fibrosis in rats. Hepatology 2004;40:1106-15.
14. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of imcomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599-607.
15. Wilson HM, Stewart KN, Brown PA et al. Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. Mol Ther 2002;6:710-7.